Dublin, March 20, 2023 (GLOBE NEWSWIRE) -- The "Large Molecule Drug Substance CDMO Market Size, Share & Trends Analysis Report By Service (Contract Manufacturing, Contract Development), By Source, By End-user, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
The global large molecule drug substance CDMO market size is expected to reach USD 22.1 billion by 2030., expanding at a CAGR of 9.3% from 2023 to 2030.
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Eurofins Scientific
- Wuxi Biologics
- Samsung Biologics
- Catalent, Inc.
- Rentschler Biopharma Se
- Agc Biologics
- Recipharm Ab (Publ)
- Siegfried Holding AG
- Boehringer Ingelheim
- Fujifilm Diosynth Biotechnologies
Rising incidence of infectious diseases and high demand for novel therapeutics are the key factors driving the market.
Contract manufacturing is one of the major steps in large molecule production and accounts for a sizable portion of the large molecule drug substance market. The mode of manufacturing is an important factor to consider because it represents the sector's outsourcing and in-house activities.
Companies are now choosing to outsource services due to high costs and delays in time. This has resulted in a greater proportion of large molecules being outsourced by the firms.
A contract development and manufacturing organization (CDMO) is a company that provides a comprehensive range of services to the pharmaceutical industry from drug development to manufacturing. CDMOs provide critical services by incorporating third-party projects and offering their knowledge, development, and manufacturing capabilities.
Prior to the COVID-19 pandemic, large molecule drug investment was increasing as it offers a plethora of new treatment options. The valuation of biologics became clearer during the race to develop therapeutics and vaccines against the SARS-CoV-2 virus.
The demand for both high-volume and high-quality CGMP drug substance and drug product manufacturing services has risen dramatically, particularly for CDMOs capable of providing a wide range of COVID vaccine technologies and, to a lesser extent, therapeutic monoclonal antibody products.
Large Molecule Drug Substance CDMO Market Report Highlights
- The contract manufacturing service segment dominated the market with a revenue share of over 65.0% in 2022
- Based on source, the mammalian segment accounted for the largest share of over 55.0% in 2022. This category will expand as more complex biologics, such as bi- and tri-specific antibodies, and antibody-drug conjugates are evolved
- Based on end-user, the biotech companies segment accounted for the largest share of over 40.0% in 2022. Rising R&D investment by the firms for large molecules drives the market
- Asia Pacific is projected to register the fastest CAGR of 10.4% during the forecast period. The large patient base, lower overall costs, skilled workforce, and changes in the regulatory scenario are the key factors driving the market
Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Large Molecule Drug Substance CDMO Market: Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Ancillary market outlook
3.2 Market Variable Analysis
3.2.1 Market driver analysis
3.2.1.1 Increasing large molecule drug approvals
3.2.1.2 Rising incidence of infectious diseases,
3.2.1.3 Higher capital investments by pharma and biotech firms in advanced technologies for establishing partnerships with CDMOs
3.2.2 Market restraint analysis
3.2.2.1 Compliance issues while outsourcing
3.2.2.2 Changing scenarios within developing countries
3.3 Large Molecule Drug Substance CDMO Market: Analysis Tools
3.3.1 Porter's Five Forces Analysis
3.3.2 Pestel Analysis
3.3.3 Major Deals & Strategic Alliances Analysis
3.3.3.1 Mergers And Acquisitions
3.3.3.2 Expansions
3.3.3.3 Agreement & Collaborations
3.4 Covid-19 Impact and Reformation Analysis
Chapter 4 Large Molecule Drug Substance CDMO Market: Service Segment Analysis
4.1 Large Molecule Drug Substance CDMO Market: Definition & Scope
4.2 Large Molecule Drug Substance CDMO Market: Market Share Analysis, 2022 & 2030
4.3 contract Manufacturing
4.3.1 Contract Manufacturing Services Market, 2018 - 2030 (USD Million)
4.3.2 Clinical
4.3.2.1 Clinical, 2018 - 2030 (USD Million)
4.3.3 commercial
4.3.3.1 Commercial market, 2018 - 2030 (USD Million)
4.4 Contract Development
4.4.1 Contract Development Market, 2018 - 2030 (USD Million)
4.4.2 Cell Line Development
4.4.2.1 Cell Line Development Market, 2018 - 2030 (USD Million)
4.4.3 Process Development
4.4.3.1 Process Development Market, 2018 - 2030 (USD Million)
Chapter 5 Large Molecule Drug Substance CDMO Market: Source Segment Analysis
5.1 Large Molecule Drug Substance CDMO Market: Definition & Scope
5.2 Large Molecule Drug Substance CDMO Market: Market Share Analysis, 2022 & 2030
5.3 Mammalian
5.3.1 Mammalian Market, 2018 - 2030 (USD Million)
5.4 Microbial
5.4.1 Microbial Market, 2018 - 2030 (USD Million)
5.5 Others
5.5.1 Others Market, 2018 - 2030 (USD Million)
Chapter 6 Large Molecule Drug Substance CDMO Market: End-user Segment Analysis
6.1 Large Molecule Drug Substance CDMO Market: Definition & Scope
6.2 Large Molecule Drug Substance CDMO Market: Market Share Analysis, 2022 & 2030
6.3 Biotech Companies
6.3.1 Biotech Companies Market, 2018 - 2030 (USD Million)
6.4 CRO
6.4.1 CRO Market, 2018 - 2030 (USD Million)
6.5 Others (Pharma Companies, Government, Research Institutes, Academic Institutes, Etc.)
6.5.1 Others (Pharma Companies, Government, Research Institutes, Academic Institutes, Etc.) Market, 2018 - 2030 (USD Million)
Chapter 7 Large Molecule Drug Substance CDMO Market: Regional Analysis
Chapter 8 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/7soaoi
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
